atropine.txt

• Atropine
• Atropair
• Sal-Tropine
• Ophthalmic: Atropisol, Isopto Atropine

Anticholinergic agent

• Parasympatholytic: inhibits action of acetylcholine at postganglionic parasympathetic neuroeffector sites
• Increases heart rate in life-threatening bradydysrhythmias

• Hemodynamically significant bradycardia
• Organophosphate poisoning

• Tachycardia
• Hypersensitivity
• Unstable cardiovascular status in acute hemorrhage and myocardial ischemia
• Narrow-angle glaucoma

• Headache
• Dizziness
• Palpitations
• Nausea/Vomiting
• Tachycardia
• Dysrhythmias
• Anticholinergic effects (blurred vision, dry mouth, urinary retention)
• Paradoxical bradycardia when pushed slowly or at low doses
• Flushed (hot dry skin)

• Potential adverse effects when administered with digoxin, cholinergics, physostigmine
• Effects enhanced by antihistamines, procainamide, quinidine, antipsychotics, benzodiazepines and antidepressants

• Prefilled syringes: 1.0 mg in 10 ml of solution.
• Injection Solution as Sulfate: 0.5mg/ml (1ml); 1mg/ml (1ml); 0.1mg/ml (5ml,10ml); 0.4mg/ml (1ml, 20ml)
• Autoinjectors: supplied with other medications, for use as a Nerve Agent Antidote

• Bradydysrhythymias: 0.5 mg IV/IO every 3-5 minutes as needed to maximum total dose of 3mg (pacing is first-line therapy)
• Organophosphate Poisoning Management: 2.0-5.0 mg IV/IO

Bradydysrhythmias: 0.02 mg/kg IV/IO (minimum single dose 0.1mg, maximum single dose 1.0mg) (epinephrine is first-line therapy)

• Onset: Immediate
• Peak Effect: Rapid to 1-2 minutes
• Duration: 2-6 hours

• Pregnancy Safety: Category C
• Moderate doses dilate pupils
• Was routinely administered for Asystole/PEA prior to release of the 2010 AHA ECC Guidelines changes. (1mg q. 3-5 min. max 3mg)